These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28837184)

  • 1. Checkpoint inhibitors: a cutting edge in oncology.
    Jago C
    Drugs Today (Barc); 2017 Jul; 53(7):399-404. PubMed ID: 28837184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Benefits of combining chemotherapy with immuno- oncology therapies or "Is it true that chemotherapy destroys the immune system?"].
    Kocsis J
    Magy Onkol; 2019 Sep; 63(3):202-207. PubMed ID: 31533140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Older Adults.
    Elias R; Morales J; Rehman Y; Khurshid H
    Curr Oncol Rep; 2016 Aug; 18(8):47. PubMed ID: 27287329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intellectual property issues of immune checkpoint inhibitors.
    Storz U
    MAbs; 2016; 8(1):10-26. PubMed ID: 26466763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends.
    Posa A; Contegiacomo A; Ponziani FR; Punzi E; Mazza G; Scrofani A; Pompili M; Goldberg SN; Natale L; Gasbarrini A; Sala E; Iezzi R
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cracking the mild, difficult and fiendish codes within and downstream of the EGFR to link diagnostics and therapeutics.
    Waterfield M
    Biochem Soc Trans; 2007 Feb; 35(Pt 1):1-6. PubMed ID: 17212578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
    Butterfield LH; Disis ML; Fox BA; Kaufman DR; Khleif SN; Wang E;
    J Immunother Cancer; 2018 Dec; 6(1):138. PubMed ID: 30514399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology.
    Dracopoli NC; Boguski MS
    Trends Pharmacol Sci; 2017 Jan; 38(1):41-54. PubMed ID: 27789023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New frontiers in oncology: Immune checkpoint inhibitors in combination therapy.
    Romano G; Gawlinski A
    Drugs Today (Barc); 2017 Feb; 53(2):103-115. PubMed ID: 28387388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.
    Vermaelen K; Waeytens A; Kholmanskikh O; Van den Bulcke M; Van Valckenborgh E
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):166-177. PubMed ID: 29170067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immuno-oncology race: myths and emerging realities.
    Cavnar S; Valencia P; Brock J; Wallenstein J; Panier V
    Nat Rev Drug Discov; 2017 Feb; 16(2):83-84. PubMed ID: 28148948
    [No Abstract]   [Full Text] [Related]  

  • 13. Oncology biomarkers--second annual GTCbio conference. Biomarkers for disease detection and therapeutics monitoring. 19-20 January 2009, Miami, FL, USA.
    Scholler N
    IDrugs; 2009 Apr; 12(4):207-10. PubMed ID: 19350459
    [No Abstract]   [Full Text] [Related]  

  • 14. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.
    Hickey RM; Kulik LM; Nimeiri H; Kalyan A; Kircher S; Desai K; Riaz A; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2017 Nov; 28(11):1487-1494. PubMed ID: 28912090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
    Annapragada A; Sikora A; Bollard C; Conejo-Garcia J; Cruz CR; Demehri S; Demetriou M; Demirdjian L; Fong L; Horowitz M; Hutson A; Kadash-Edmondson K; Kufe D; Lipkin S; Liu S; McCarthy C; Morgan M; Morris Z; Pan Y; Pasquini M; Schoenberger S; Van Allen E; Vilar E; Xing Y; Zha W; ; Odunsi A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First advanced course on biomarkers in molecular and immuno-oncology in the Middle East.
    Moujaess E; Khoury M; Zouein J; Eid JB; Mohty R; Kourie HR
    Future Oncol; 2021 Aug; 17(22):2831-2834. PubMed ID: 34148366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
    Sharma P
    Cancer J; 2016; 22(2):68-72. PubMed ID: 27111900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing and validating model systems for immuno-oncology.
    McCarthy CE; Zahir N; Eljanne M; Sharon E; Voest EE; Palucka K
    Cancer Cell; 2021 Aug; 39(8):1018-1022. PubMed ID: 34115988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDO inhibitors move center stage in immuno-oncology.
    Sheridan C
    Nat Biotechnol; 2015 Apr; 33(4):321-2. PubMed ID: 25850038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.